Company News
Relay Therapeutics Zovegalisib Targets $8B Market
TD Cowen analyst Yaron Werber rates Relay Therapeutics a Buy, citing zovegalisib as a best‑in‑class PI3Kα inhibitor drug.
In second‑line PIK3CA‑mutant metastatic breast cancer, zovegalisib + fulvestra
